NO20080434L - Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien - Google Patents

Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien

Info

Publication number
NO20080434L
NO20080434L NO20080434A NO20080434A NO20080434L NO 20080434 L NO20080434 L NO 20080434L NO 20080434 A NO20080434 A NO 20080434A NO 20080434 A NO20080434 A NO 20080434A NO 20080434 L NO20080434 L NO 20080434L
Authority
NO
Norway
Prior art keywords
inhibitors
respiratory tract
tissue factor
inflammatory conditions
conditions affecting
Prior art date
Application number
NO20080434A
Other languages
English (en)
Norwegian (no)
Inventor
Lars Otto Uttenthal
Original Assignee
Drugrecure Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugrecure Aps filed Critical Drugrecure Aps
Publication of NO20080434L publication Critical patent/NO20080434L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
NO20080434A 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien NO20080434L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69396805P 2005-06-24 2005-06-24
PCT/IB2006/002602 WO2006136962A2 (en) 2005-06-24 2006-06-23 Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Publications (1)

Publication Number Publication Date
NO20080434L true NO20080434L (no) 2008-03-17

Family

ID=37570814

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080434A NO20080434L (no) 2005-06-24 2008-01-23 Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20080433A NO20080433L (no) 2005-06-24 2008-01-23 Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene

Country Status (14)

Country Link
US (3) US8088728B2 (cg-RX-API-DMAC7.html)
EP (3) EP1898945B1 (cg-RX-API-DMAC7.html)
JP (3) JP2008543926A (cg-RX-API-DMAC7.html)
KR (2) KR20080071116A (cg-RX-API-DMAC7.html)
CN (2) CN101262880A (cg-RX-API-DMAC7.html)
AU (2) AU2006273696B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0613137A2 (cg-RX-API-DMAC7.html)
CA (2) CA2612597C (cg-RX-API-DMAC7.html)
DK (3) DK1896059T3 (cg-RX-API-DMAC7.html)
IL (2) IL188221A0 (cg-RX-API-DMAC7.html)
NO (2) NO20080434L (cg-RX-API-DMAC7.html)
RU (2) RU2496515C2 (cg-RX-API-DMAC7.html)
WO (3) WO2007012976A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA200800251B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010512350A (ja) * 2006-12-11 2010-04-22 ダラグレキュル・アンパルトセルスカブ ホスホマイシンの肺投与により細菌感染を伴う嚢胞性線維症または肺炎を処置するための方法
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
CA3036553A1 (en) * 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
SE9200541D0 (sv) * 1992-02-24 1992-02-24 Kabi Pharmacia Ab New usee of omega-3-fatty acids
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
ATE321846T1 (de) * 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c
US6497877B1 (en) * 1997-01-29 2002-12-24 University Technology Corporation Plasminogen activator as an anti-inflammatory agent
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6049577A (en) * 1998-05-28 2000-04-11 Glenayre Electronics, Inc. Header synchronization detector
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
JP4848092B2 (ja) * 2000-02-01 2011-12-28 石原産業株式会社 ジアミノトリフルオロメチルピリジン誘導体を含有する肺不全の治療剤又は予防剤
AU2001232736A1 (en) * 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6933367B2 (en) * 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
IL158615A0 (en) * 2001-05-02 2004-05-12 Novo Nordisk As Modified factor vii in treatment of acute lung injury or acute respiratory distress syndrome
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
BR0213293A (pt) * 2001-10-15 2004-12-21 Chiron Corp Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
KR100674315B1 (ko) * 2002-02-08 2007-01-24 에스케이 주식회사 가열로 튜브 세척제 및 세척방법
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
ES2321297T3 (es) * 2003-01-08 2009-06-04 Novartis Vaccines And Diagnostics, Inc. Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular.
EP1609471A1 (en) * 2003-03-31 2005-12-28 Kyowa Hakko Kogyo Co., Ltd. Remedy and/or preventive for lung diseases
WO2005042011A1 (en) * 2003-11-04 2005-05-12 Novo Nordisk A/S Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
CA2582353A1 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway

Also Published As

Publication number Publication date
RU2008102655A (ru) 2009-07-27
EP1906994B1 (en) 2014-04-23
EP1896059B1 (en) 2012-12-19
US20100160218A1 (en) 2010-06-24
WO2006136962A2 (en) 2006-12-28
DK1898945T3 (da) 2013-03-25
JP2013151510A (ja) 2013-08-08
IL188220A0 (en) 2008-03-20
DK1906994T3 (da) 2014-07-21
US8088728B2 (en) 2012-01-03
AU2006273696A1 (en) 2007-02-01
WO2006136962A3 (en) 2007-07-12
CA2612646C (en) 2015-11-24
WO2007012976A3 (en) 2007-07-12
CA2612597C (en) 2015-03-31
BRPI0613137A2 (pt) 2010-12-21
CA2612597A1 (en) 2007-02-01
WO2007012976A2 (en) 2007-02-01
BRPI0611710A2 (pt) 2011-12-20
NO20080433L (no) 2008-03-19
ZA200800255B (en) 2009-04-29
CN101262880A (zh) 2008-09-10
ZA200800251B (en) 2009-04-29
HK1114567A1 (en) 2008-11-07
DK1896059T3 (da) 2013-04-08
AU2006273696B2 (en) 2012-08-30
EP1898945A2 (en) 2008-03-19
WO2006136963A2 (en) 2006-12-28
IL188221A0 (en) 2008-03-20
EP1906994A2 (en) 2008-04-09
US20100297099A1 (en) 2010-11-25
RU2008102656A (ru) 2009-07-27
EP1898945B1 (en) 2012-12-19
AU2006260599A1 (en) 2006-12-28
EP1896059A2 (en) 2008-03-12
RU2496516C2 (ru) 2013-10-27
KR20080071116A (ko) 2008-08-01
US20100279925A1 (en) 2010-11-04
KR20080074085A (ko) 2008-08-12
WO2006136963A3 (en) 2007-07-12
JP2008543925A (ja) 2008-12-04
CA2612646A1 (en) 2006-12-28
RU2496515C2 (ru) 2013-10-27
CN101262879B (zh) 2013-04-10
JP2008543926A (ja) 2008-12-04
CN101262879A (zh) 2008-09-10

Similar Documents

Publication Publication Date Title
Butterfield The Power of Anacrusis
NO20072466L (no) Fremgangsmate for a forhindre og behandle strukturendring i luftveier og pulmonal inflammasjon ved a anvende A2B-adenosinreseptorantagonister
WO2006130873A3 (en) Methods and devices for maintaining surgically created channels in a body organ
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
WO2008069972A3 (en) Systems for effecting cessation of tobacco use
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2007091266A3 (en) Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
WO2006130821A3 (en) Methods and devices for maintaining surgically created channels in a body organ
NO20070987L (no) Polysulfaterte glykosider og salter av disse.
NO20082434L (no) Materialer og fremgangsmater for behandling av kroniske fibrotiske sykdommer
DK1718336T3 (da) Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
BR112015008725A2 (pt) método para determinar a presença ou ausência de uma infecção bacteriana em um indivíduo
NO20080433L (no) Luftveisadministrering av aktivt protein C i inflammatoriske tilstander som pavirker luftveiene
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2004043392A3 (en) Mucin synthesis inhibitors
NO20071824L (no) Fremgangsmater til a behandle trakeale, bronkiale eller alveolaere blodninger eller hemoptyse
NO20075662L (no) Roflumilast for behandlingen av pulmonal hypertensjon
AU2006329199A8 (en) Treatment of respiratory diseases
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin
SE0401631D0 (sv) New Composition
WO2004113286A3 (en) Mucin synthesis inhibitors
NI200700039A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38.